NASDAQ: AVTE - Aerovate Therapeutics, Inc.

Yield per half year: +64.81%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Aerovate Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-06-30
ISIN US0080641071
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://aerovatetx.com
Цена ао 25.65
Change price per day: +1.52% (2.63)
Change price per week: +5.53% (2.53)
Change price per month: +1.14% (2.64)
Change price per 3 month: +29.61% (2.06)
Change price per half year: +64.81% (1.62)
Change price per year: -88.2% (22.63)
Change price per 3 year: -72.42% (9.68)
Change price per 5 year: 0% (2.67)
Change price per 10 year: 0% (2.67)
Change price per year to date: +8.98% (2.45)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 5.58 2
P/E 0 0
EV/EBITDA -7.23 0
Total: 2.25

Efficiency

Title Value Grade
ROA, % -59.27 0
ROE, % -69 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0083 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 2364.03 10
Yield EPS, % 104.86 10
Total: 8
More

Institutions Volume Share, %
RA Capital Management, L.P. 8263982 29.66
Sofinnova Investments, Inc. 3758686 13.49
Tcg Crossover Management, Llc 2201274 7.9
Atlas Venture Life Science Advisors, LLC 2039249 7.32
Baker Brothers Advisors, LLC 1680517 6.03
Cormorant Asset Management, LP 1211696 4.35
Frazier Life Sciences Management, L.P. 1204867 4.32
Driehaus Capital Management, LLC 1058209 3.8
Great Point Partners LLC 1037690 3.72
Orbimed Advisors LLC. 756930 2.72

ETF Share, % Profitability for 1 year, % Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.06121 63.04 0.33
iShares Micro-Cap ETF 0.00658 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00201 38.04 0.6026
ProShares UltraPro Russell2000 0.00055 89.82 1.47873
ProShares Hedge Replication ETF 0.00016 5.92 1.47892
iShares Russell 3000 ETF 0.00006 24.83 1.43482
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Mr. Timothy P. Noyes M.B.A. CEO & Director 936.9k 1962 (63 years)
Mr. George A. Eldridge CFO & Treasurer 658.6k 1963 (62 years)
Dr. Marinus Verwijs Ph.D. Chief Technical Officer 439.88k 1976 (49 years)
Dr. Benjamin T. Dake Ph.D. Founder, President, COO & Secretary 435.5k 1976 (49 years)
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S Chief Scientific Officer 372.33k 1960 (65 years)
Mr. Hunter Gillies M.D. Chief Medical Officer 512.74k 1966 (59 years)
Mr. Timothy J. Pigot Chief Commercial Officer 584.6k 1971 (54 years)
Ms. Donna Dea Head of Regulatory Affairs N/A
Ms. Susan Fischer Executive Vice President of Development Operations N/A
Mr. Stephen K. Yu Senior Vice President of Quality N/A

Address: United States, Waltham. MA, 930 Winter Street - open in Google maps, open in Yandex maps
Website: https://aerovatetx.com